Among secondary endpoints, the dapagliflozin combination group achieved a significantly greater adjusted mean reduction from baseline in two-hour postprandial glucose (-74 mg/dL vs -38 mg/dL ...

AstraZeneca Pharma India on Monday said it has received approval for extended indication from the Drugs Controller General of India for Dapagliflozin 10 mg tablets. View in App The receipt of this ...

The company has "received Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the DCGI for Dapagliflozin tablets 10 mg," AstraZeneca Pharma India said in a filing to BSE.

LONDON (Alliance News) - AstraZeneca (AZN, AZN.L) and Bristol-Myers Squibb Company (BMY), Tuesday said Dapagliflozin, an inhibitor used along with a controlled combination of Metformin and ...

Bristol-Myers Squibb Company (BMY) and AstraZeneca (AZN) announced results from a Phase 3 clinical study that showed the investigational compound dapagliflozin 10 mg demonstrated significant ...

Bristol-Myers Squibb and AstraZeneca announced positive results from a Phase 3 study of dapagliflozin as add-on therapy to metformin for the treatment of type 2 diabetes.

Dapagliflozin 10 mg: 47% (dapagliflozin plus metformin XR) vs. 32% ... AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, ...

In the study examining dapagliflozin 10 mg, 638 patients were treated as follows: dapagliflozin 10 mg plus metformin XR (n=211), dapagliflozin 10 mg plus placebo (n=219) or metformin XR plus ...

Dapagliflozin 10 mg significantly reduced mean systolic blood pressure (-4.8 mm Hg) vs placebo (-1.7 mm Hg) from baseline to week 24 (difference -3.1 mm Hg, p < 0.05). The DERIVE trial also ...

Dapagliflozin as Monotherapy Demonstrated Improved ... achieved statistically significant mean reductions at 5 mg and 10 mg doses once daily in the ... (NYSE: BMY) and AstraZeneca ...

Bristol-Myers Squibb Company and AstraZeneca announced results from their Phase 3 trial of dapagliflozin (as monotherapy) for treatment-naïve adults with type 2 diabetes.

In the study examining dapagliflozin 10 mg, 638 patients were treated as follows: dapagliflozin 10 mg plus metformin XR (n=211), dapagliflozin 10 mg plus placebo (n=219) or metformin XR plus ...